Progressive multifocal leukoencephalopathy (PML), an often-fatal neurodegenerative disease, is caused by the neuroinvasive polyomavirus JCPyV. Peripheral organs, including the kidney, are the site of lifelong persistent infections that are asymptomatic. In a subset of immunosuppressed or immunomodulated patients, the virus invades the central nervous system infecting oligodendrocytes, which leads to the multifocal white matter disease known as PML. The mechanisms that lead to neuroinvasion by JCPyV have not been well described. The brain is protected from viruses and other pathogens by physiological barriers, including the blood-cerebrospinal fluid barrier and the blood-brain barrier. To better understand the mechanism by which the virus breaches these barriers, we focused our attention on studying virus interactions with pericytes, which are an essential component of the blood-brain barrier. We found that the virus binds to pericytes in a receptor-dependent manner and that pericytes are susceptible to JCPyV infection. Previous work from our group demonstrated that JCPyV was capable of penetrating an intact endothelial cell barrier. Once across the endothelium, JCPyV would come in direct contact with pericytes, and we hypothesize pericyte infection would amplify and facilitate robust penetration into the brain parenchyma. This is the first demonstration that pericytes, a principal component of the blood-brain barrier, are susceptible to the neuroinvasive human polyomavirus JCPyV. IMPORTANCE: JCPyV infects at least half the adult population worldwide. An asymptomatic, persistent infection is typically established in the kidney and possibly other peripheral organs. In immunosuppressed individuals, the virus can reactivate and cause progressive multifocal leukoencephalopathy, a deadly disease of the central nervous system (CNS). The pathogenic route the virus takes from the periphery to the CNS is unknown. Here, we demonstrate for the first time that JCPyV can infect human cerebrovascular pericytes, a cell type that contributes to the blood-brain barrier. This observation suggests that the virus could use the pericytes as a means to penetrate the blood-brain barrier to reach its pathogenic targets in the brain parenchyma.
JC polyomavirus (JCPyV) is a double-stranded DNA virus that causes progressive multifocal leukoencephalopathy (PML), a demyelinating disease with a high rate of morbidity and mortality. There are limited treatment options for patients diagnosed with PML, and most involve reconstitution of immunological functions. In this paper, we show that flavonols, specifically quercetin, myricetin, and fisetin, significantly reduce JCPyV infection in human glial cells. We further show that quercetin and fisetin can suppress viral spread in an already established infection, suggesting therapeutic viability of these drugs as antivirals. Additional research is required to determine the mechanism of action of flavonols in inhibiting JCPyV infection and to investigate whether these compounds have the potential to cross the blood-brain barrier in significant amounts to inhibit the virus in the brain parenchyma. IMPORTANCE: The human polyomavirus, JC polyomavirus (JCPyV), causes significant morbidity and mortality in immunosuppressed or immunomodulated patients. There are no approved antivirals to treat JCPyV-induced disease. Flavonols are naturally occurring polyphenolic compounds that are known to antagonize pathways involved in JCPyV infection. Several flavonols were found to inhibit initial JCPyV infection and viral spread in a glial cell line and in normal human glial cells. These represent a promising new treatment paradigm for patients at risk of suffering from JCPyV-induced disease.
BK and JC Polyomaviruses (BKPyV and JCPyV) are ubiquitous human pathogens capable of establishing lifelong, asymptomatic persistence in the majority of the global population. While decades of research have focused on their lytic replication cycles and the development of severe diseases, such as polyomavirus-associated nephropathy (PVAN) caused by BKPyV and progressive multifocal leukoencephalopathy (PML) caused by JCPyV, their primary evolutionary strategy is one of persistence rather than pathogenesis. This review shifts the perspective from a replication-centric framework towards an evolutionary persistence model, detailing the multi-layered host and viral determinants that maintain the homeostatic balance. At the cellular level, viral genomes are restricted by chromatinization into minichromosomes and host S-phase licensing. These constraints are reinforced by innate immune sensing and adaptive T-cell and antibody responses that curtail systemic dissemination while permitting periodic, low-level urinary shedding, which is essential for horizontal transmission. In addition to these host barriers, the viruses utilize intrinsic regulatory mechanisms to prevent excessive replication and immune detection, including the stable archetype non-coding control region (NCCR), viral microRNAs that downregulate early gene expression, and the small t antigen (STAg). Finally, we address unresolved questions regarding the full spectrum of cellular reservoirs, the molecular triggers of reactivation, and the ecological factors shaping their transmission routes. Understanding these maintenance mechanisms is crucial for refining clinical interventions and managing the rare, devastating transitions from silent persistence to lytic disease.